TABLE 1.

Subject characteristics for the 36 patients enrolled and the 27 patients with evaluable pharmacokinetic sampling

CharacteristicaAll accrued subjects (n = 36)Subjects with adequate pharmacokinetic assessments (n = 27)
Group A (n = 21)Group B (n = 15)Group A (n = 14)Group B (n = 13)
Gender (no. of subjects)
    Male12998
    Female9655
Race or ethnicity (no. of subjects)
    White, non-Hispanic1211
    Black, non-Hispanic16111210
    Hispanic4212
No. of subjects at age (yr):
    <152312
    15 to <185232
    ≥181410109
    Median*19.7 (17.0, 21.4)20.0 (17.2, 22.7)19.8 (17.8, 21.4)20.0 (18.0, 22.3)
Baseline CD4+ count (cells/mm3)
    250-5009664
    >500-1,00011585
    >1,0000202
    Missing1002
    Median*550 (425, 640)531 (421, 830)550 (378, 620)670 (421, 935)
Treatment regimen
    PI9252
    Non-NRTI1112810
    Both PI and non-NRTI1111
  • a *, The 25th and 75th percentiles are given in parentheses. PI, protease inhibitor.